Psychiatry
The global landscape of the burden of depressive symptoms/major depression in individuals living with HIV/AIDs and its effect on antiretroviral medication adherence.
10 Jun, 2022 | 10:31h | UTC
Meta-Analysis: Prevalence of depression among caregivers of cancer patients.
10 Jun, 2022 | 10:33h | UTC
Systematic Review: Cannabis-based products for chronic pain.
7 Jun, 2022 | 11:47h | UTCCannabis-Based Products for Chronic Pain: A Systematic Review – Annals of Internal Medicine
Annals Video Summary: Cannabis-Based Products for Chronic Pain: A Systematic Review
Summary for Patients: Cannabis-Based Products for Chronic Pain
Related:
Podcast: #338 LIVE! Medical Cannabis: Is it still dope? – The Curbsiders
M-A: Birth outcomes of neonates exposed to marijuana in utero.
Cannabis-related allergies: an international overview and consensus recommendations.
Review: Cannabis-based medicines and medical cannabis for chronic neuropathic pain.
Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain.
Cannabis products are being sold as sleep remedies – here’s the evidence about their effectiveness.
Guideline: Medical cannabis or cannabinoids for chronic pain.
NICE Guideline: Cannabis-Based Medicinal Products
Short Review: Drug Interactions with Cannabinoids
Meta-Analysis: Cannabinoids Not Effective for Cancer-Related Pain
Review: Considerations for cannabinoids in perioperative care by anesthesiologists.
Review: Cannabis-based Medicines and the Perioperative Physician
Perspective: If You Smoke Pot, Your Anesthesiologist Needs To Know
M-A: How do income changes impact on mental health and wellbeing for working-age adults?
7 Jun, 2022 | 11:21h | UTCInvited commentary: The impact of income on mental health
Commentary from the author on Twitter (thread – click for more)
Our ?️ #SystematicReview in @TheLancetPH looks at how income changes impact on #MentalHealth & #Wellbeing ?? We find income likely does have a causal effect on mental health & that effects are much bigger (up to 13x) for moves into/out of poverty [1/5] https://t.co/A4rukCOA4a
— Rachel Thomson (@Rachel_Thomson) June 2, 2022
M-A: The prevalence of comorbid serious mental illnesses and substance use disorders in prison populations.
7 Jun, 2022 | 11:20h | UTCInvited Commentary: The prevalence of comorbid substance use disorders and serious mental illnesses in prisons
Efficacy of neurostimulation across mental disorders: systematic review and meta-analysis of 208 randomized controlled trials.
6 Jun, 2022 | 10:53h | UTC
RCTs: Efficacy, safety, and tolerability of Centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder.
3 Jun, 2022 | 11:21h | UTC
AAP Policy Statement: Recommended terminology for substance use disorders in the care of children, adolescents, young adults, and families.
2 Jun, 2022 | 11:00h | UTC
Commentary from one of the authors on Twitter (thread – click for more)
1/New @AmerAcadPeds policy statement led by @DrRachelAlinsky with @jquigleymd @DrScottHadland – Terminology for Substance Use Disorders in the Care of Children, Adolescents, Young Adults, and Families.
I'm proud to be a part & there's a cool backstory!https://t.co/CkxtS9BYxN
— Stephen Patrick, MD, MPH (@stephenwpatrick) May 25, 2022
M-A: Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response.
2 Jun, 2022 | 10:32h | UTCAntidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis – Journal of Affective Disorders (link to abstract – $ for full-text)
Commentaries:
Antidepressant Effect Sizes Modest for Pediatric Major Depressive Disorder – Consultant360
Commentary on Twitter
MA: The SMD among all studies of antidepressants in C&A with MDD was 0.12 (0.08-0.17), a very small ES, lower than that seen in studies of adults with MDD. When the MA was limited to studies with a low mean placebo response, the SMD increased to 0.19 https://t.co/hPYvta4rgf
— PfOL (@psychopharmacol) March 23, 2022
Cohort Study: Evaluation of neurologic and psychiatric outcomes after hospital discharge among adult survivors of cardiac arrest.
2 Jun, 2022 | 10:15h | UTC
M-A: Prevalence and correlates of suicide and nonsuicidal self-injury in children.
31 May, 2022 | 10:48h | UTCPrevalence and Correlates of Suicide and Nonsuicidal Self-injury in Children: A Systematic Review and Meta-analysis – JAMA Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
In this meta-analysis of self-harm in children, suicidal ideation, #suicide attempts and nonsuicidal self-injury occurred at concerning rates. Males, child maltreatment, ADHD and depression may be linked to risk. https://t.co/Nw25EuKfwW @rachel__walsh @AnaSheehan19 @csanzari_
— JAMA Psychiatry (@JAMAPsych) May 25, 2022
Study Commentary: Cerebrospinal fluid biomarkers for depression.
25 May, 2022 | 10:59h | UTCCerebrospinal fluid biomarkers for depression – The Mental Elf
Original Study: Cerebrospinal Fluid Biomarkers in Patients With Unipolar Depression Compared With Healthy Control Individuals: A Systematic Review and Meta-analysis – JAMA Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
Comprehensive systematic review and meta-analysis of all cerebrospinal fluid studies in #depression investigating contrast to healthy controls (165 biomarkers from 97 studies) pointing at several biological mechanisms and future directions. https://t.co/gcjFBjYJhi @MichaelBenros
— JAMA Psychiatry (@JAMAPsych) April 25, 2022
Cohort Study: Analysis of neuropsychiatric diagnoses after montelukast initiation.
25 May, 2022 | 11:05h | UTCAnalysis of Neuropsychiatric Diagnoses After Montelukast Initiation – JAMA Network Open
Related:
Adverse drug reactions of montelukast in children and adults – Pharmacology Research & Perspectives
Commentary on Twitter
This cohort study of patients with asthma or allergic rhinitis found montelukast use is associated with higher odds of neuropsychiatric outcomes, including anxiety and insomnia. https://t.co/HAzcADsHZc
— JAMA Network Open (@JAMANetworkOpen) May 24, 2022
Guidelines for human rights and privileges of mentally ill persons.
24 May, 2022 | 08:05h | UTC
Podcast: Updates in addiction medicine.
24 May, 2022 | 07:58h | UTC#336 Updates in Addiction Medicine: Live From SGIM – The Curbsiders
Systematic Review: Landscaping the evidence of intimate partner violence and postpartum depression.
20 May, 2022 | 10:44h | UTC
Psychogenic nonepileptic seizure: An empathetic, practical approach.
19 May, 2022 | 10:30h | UTCEditorial: Psychogenic nonepileptic seizure: A neurologist’s perspective
Systematic Review: The effects of breastfeeding on maternal mental health.
18 May, 2022 | 10:29h | UTC
Alcohol withdrawal syndrome: identification and management.
17 May, 2022 | 10:37h | UTCAlcohol Withdrawal Syndrome: Identification and Management – emDocs
Podcast: Generalized anxiety disorder pearls.
17 May, 2022 | 10:35h | UTC#335 Generalized Anxiety Disorder – The Curbsiders
Cohort Study: Antipsychotic use during pregnancy and risk for gestational diabetes.
17 May, 2022 | 10:24h | UTC
Commentary on Twitter
cohort study: Olanzapine, clozapine and quetiapine used during pregnancy were associated with increased risks for gestational diabetes (aRR=1.8; 1.3–2.4) and the infant being large for gestational age (aRR=1.6; 1.3–1.9) vs. untreated pregnant women https://t.co/VxmAxU9w4n
— PfOL (@psychopharmacol) May 12, 2022
M-A: Efficacy and tolerability of repetitive transcranial magnetic stimulation on suicidal ideation.
17 May, 2022 | 10:25h | UTC
Commentary on Twitter
MA: rTMS significantly reduced suicidal ideation (g= −0.390; −0.193 to −0.588) and severity of depressive symptoms (g= −0.698; −1.023 to −0.372) in patients with major mental disorders https://t.co/TBSfG5GIL0 pic.twitter.com/QX06EX8Hog
— PfOL (@psychopharmacol) May 11, 2022
Under a CC BY license
EAP Recommendations: Adolescents with eating disorders in pediatric practice.
16 May, 2022 | 02:12h | UTC
Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors.
16 May, 2022 | 01:55h | UTC
Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale.
16 May, 2022 | 01:45h | UTC
Commentary on Twitter
SR: there is moderate evidence of the efficacy of gabapentinoids in anxiety states (SMD ranging between -2.25 and -0.25), but minimal evidence in bipolar disorder and insomnia and they should be used for these disorders only with strong justification https://t.co/zrxduX2q6l pic.twitter.com/6mKYwHKKbo
— PfOL (@psychopharmacol) May 12, 2022
Under a http://creativecommons.org/licenses/by/4.0/ license